Company Profile
Astellas Pharma provides the research, development, manufacture, sale, and supply of pharmaceuticals in Japan and globally. The company offers XTANDI, a treatment for prostate cancer.
Its portfolio also includes XOSPATA, a treatment for acute myeloid leukemia, VYLOY, a treatment for gastric adenocarcinoma and esophagogastric junction adenocarcinoma, and PADCEV, a treatment for patients with metastatic urothelial carcinoma VEOZAH, a treatment for vasomotor symptoms associated with menopause.
Its portfolio also includes IZERVAY, a treatment for age-related macular degeneration with geographic atrophy, Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder, and Prograf, an immunosuppressant.
It offers its products to oncology, ophthalmology, urology, immunology, and women's health areas. Founded in 1923 and headquartered in Chuo, Japan, Astellas Pharma was formerly known as Yamanouchi Pharmaceutical Co. Ltd. before rebranding in April 2005.